Beschreibung:
<jats:sec><jats:title>Background:</jats:title><jats:p> Depressive adverse effects of major cardiac medications in patients with cardiovascular disease have been suggested. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate the influence of the use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and/or β-blockers on subsequent depressive symptoms in patients hospitalized for acute coronary syndrome. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A sample of 521 patients was followed for 8 months during 1,340 observations. Data were collected from structured telephone interviews and medical record chart reviews. Pooled time series generalized estimating equations regression models were used to evaluate depressive symptom scores, controlling for major clinical and sociodemographic patient characteristics. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> No significant independent or interactive effects were found linking the use of these medications to subsequent depressive symptoms, despite changes in depressive symptoms over time. Factors that did affect subsequent depression included sociodemographic (eg, increased age, less education) and clinical characteristics (eg, higher composite comorbidity, prior history of depression and/or first myocardial infarction, higher postdischarge pain levels). </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Our results suggest that potential depressive adverse effects should not be considered a contraindication to the use of recommended cardiac medications. Observed increases in depressive symptoms after an acute cardiac injury will more likely be attributed to other patient characteristics independent of the use of major drug therapy prescribed to prevent further acute cardiac events. </jats:p></jats:sec>